Applicant and holder: **Relaxera Pharmazeutische Gesellschaft mbH & Co. KG**

Abbreviation	country	Stat	Title/Subject	Application date	Pub.-Date	Patent-Number
RLX00218AUPC	AU	G.	Process for preparing human relaxin-2	03.08.2012	07.02.2013	AU2012291972 A1
RLX00218DEEP	DE	G.	Process for preparing human relaxin-2	03.08.2012	07.02.2013	WO2013017679
RLX00218INPC	IN	G.	Process for preparing human relaxin-2	03.08.2012	07.02.2013	WO2013017679
RLX00183DEEP	DE	G.	RLX for treating Impaired Glucose Tolerance	22.02.2013	29.08.2013	WO2013124463
RLX00183FREP	FR	G.	RLX for treating Impaired Glucose Tolerance	22.02.2013	29.08.2013	WO2013124463
RLX00183GBEP	GB	G.	RLX for treating Impaired Glucose Tolerance	22.02.2013	29.08.2013	WO2013124463
RLX00218CHEP	CH	G.	Process for preparing human relaxin-2	03.08.2012	11.06.2014	EP2739647
RLX00218FREP	FR	G.	Process for preparing human relaxin-2	03.08.2012	11.06.2014	EP2739647 (FR)
RLX00218JP	JP	G.	Process for preparing human relaxin-2	03.08.2012	28.08.2014	2014521680
RLX00218USPC	US	G.	Process for preparing human relaxin-2	03.08.2012	06.11.2014	US20140328900
RLX00183US	US	G.	RLX for treating Impaired Glucose Tolerance	22.02.2013	05.02.2015	US20150038411
RLX00182CA	CA	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	26.05.2015	WO2015177378
RLX00182AU	AU	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	26.11.2015	WO2015177378
RLX00182DEEP	DE	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	29.03.2017	EP3145534
RLX00182FREP	FR	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	29.03.2017	EP3145534
RLX00182GBEP	GB	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	29.03.2017	EP3145534
RLX00182GREP	GR	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	29.03.2017	EP3145534
RLX00182ITEP	IT	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	29.03.2017	EP3145534
RLX00182JP	JP	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	29.06.2017	2017517524

Applicant and holder: **Relaxera Pharmazeutische Gesellschaft mbH & Co. KG**

Abbreviation	country	Stat	Title/Subject	Application date	Pub.-Date	Patent-Number
RLX00182US	US	G.	RLX for treating heart failure with preserved ejection fraction	26.05.2015	29.06.2017	US 2017/0182127 A1
RLX00182US02	US	G.	RLX for increasing cardiac inflow (atrial fibrillation)	28.01.2019	16.05.2019	US-2019-0142902-A1
RLX00182JP02	JP	G.	RLX for increasing cardiac inflow (atrial fibrillation)	28.08.2019	28.11.2019	2019203022
RLX00223AUPC	AU	G.	Rlx composition for treating cardiac decompensation (cachexia, wasting)	16.11.2020	20.05.2021	WO2021094626
RLX00223USPC	US	G.	Rlx composition for treating cardiac decompensation (cachexia, wasting)	16.11.2020	20.05.2021	WO2021094626
RLX00223EPPC	EP	F.	Rlx composition for treating cardiac decompensation (cachexia, wasting)	16.11.2020	21.09.2022	EP4058048
RLX00236AUPC	AU	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	07.03.2024	WO2024047130
RLX00236CAPC	CA	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	07.03.2024	WO2024047130
RLX00236INPC	IN	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	07.03.2024	WO2024047130
RLX00257PC	WO	F.	Formulation for a daily or bi-daily relaxin-bolus	22.11.2023	20.03.2025	WO2025056188
RLX00257USPC	US	F.	Formulation for a daily or bi-daily relaxin-bolus	22.11.2023	20.03.2025	WO2025056188
RLX00236CNPC	CN	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	06.05.2025	CN119947743 A
RLX00223USPC01	US	F.	Rlx composition for treating cardiac decompensation (cachexia, wasting)	08.01.2025	15.05.2025	US20250152671
RLX00236EPPC	EP	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	09.07.2025	EP4580653
RLX00236JPPC	JP	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	28.08.2025	JP 2025-528469A
RLX00236BRPC	BR	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	02.09.2025	Journ. 2852
RLX00257EPPC	EP	F.	Formulation for a daily or bi-daily relaxin-bolus	22.11.2023	19.08.2026	EP4791358
RLX00236USPC	US	F.	Rlx as GCR agonist - Immunosuppressive medicament and method of treatment	30.08.2023	29.10.2026	US20260335412A1

Status: „G" = granted; „F" = filed